Bipolar disorder
Drug research and approvals for bipolar disorder: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 215 studies of bipolar disorder are recruiting on ClinicalTrials.gov, Health Canada has authorized 17 drug trials for it since 2013, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 215
- Trials authorized in Canada: 17
- FDA orphan approvals: 0
- EU medicines: 2
- SALUTOGENESIS MODELNCT07949994 · Not applicable · TC Erciyes University · starts Jun 1, 2026
- Preventing Mood Disorders in High-risk Offspring: Protocol for the Randomized Controlled Trial of the MARIO Online…NCT07938593 · Not applicable · Erasmus Medical Center · starts Nov 29, 2022
- Health Assessment in People With Severe Mental IllnessNCT07931456 · Not reported · University of the Basque Country (UPV/EHU) · starts Apr 17, 2026
- Affective Cognitive Training in Mood Disorders and High-risk RelativesNCT07920302 · Not applicable · Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital · starts Nov 17, 2025
- A Prospective Study of Anxiety, Depression, and Bipolar Disorder in PeopleNCT07903246 · Not reported · Second Affiliated Hospital, Zhejiang University, School of Medicine · starts Sep 15, 2026
- French Minds Cohort: a French Longitudinal and Multimodal Cohort of Patients With Major Mood Disorders, Psychotic…NCT07881016 · Not applicable · Fondation FondaMental · starts Jun 11, 2026
- Quality of Life, Safety and Compliance of Patients Using Monotherapy or Combinatorial Therapy With Quetiapine for…NCT07858565 · Not reported · Bosnalijek D.D · starts Oct 30, 2025
- Cryoneurolysis Versus Bipolar Radiofrequency Ablation of Genicular Nerves for Pain Relief in Symptomatic Knee…NCT07855367 · Not applicable · National Cancer Institute, Egypt · starts Sep 15, 2026
- State Representation in Early Psychosis 2NCT07834203 · Not reported · University of Minnesota · starts Oct 15, 2025
Approved 17
- Lithium carbonateInositol-1(or 4)-monophosphatase 1 inhibitor
- OlanzapineSerotonin 2a (5-HT2a) receptor antagonist
- AripiprazoleDopamine D2 receptor partial agonist
- LamotrigineSodium channel alpha subunit blocker
- Valproic acidSuccinate semialdehyde dehydrogenase inhibitor
- RisperidoneSerotonin 2a (5-HT2a) receptor antagonist
- QuetiapineSerotonin 2a (5-HT2a) receptor antagonist
- ZiprasidoneSerotonin 2a (5-HT2a) receptor antagonist
- AsenapineDopamine D2 receptor antagonist
- CarbamazepineSodium channel alpha subunit blocker
- CariprazineDopamine D3 receptor modulator
- LurasidoneSerotonin 2a (5-HT2a) receptor antagonist
- FluoxetineSerotonin transporter inhibitor
- LoxapineSerotonin 2a (5-HT2a) receptor antagonist
- DoxepinNorepinephrine transporter inhibitor
- Lithium citrateInositol-1(or 4)-monophosphatase 1 inhibitor
- SamidorphanMu opioid receptor antagonist
Phase 3 12 of 41
- LumateperoneSerotonin 2a (5-HT2a) receptor antagonist
- TopiramateCarbonic anhydrase II inhibitor
- SertralineSerotonin transporter inhibitor
- PaliperidoneDopamine D2 receptor antagonist
- MemantineGlutamate [NMDA] receptor negative allosteric modulator
- KetamineGlutamate [NMDA] receptor negative allosteric modulator
- CannabidiolCannabinoid CB1 receptor negative allosteric modulator
- BrexpiprazoleDopamine D2 receptor partial agonist
- EscitalopramSerotonin transporter inhibitor
- RamelteonMelatonin receptor agonist
- AspirinCyclooxygenase inhibitor
- MinocyclineBacterial 70S ribosome inhibitor
Phase 2 12 of 42
- AcetylcysteineGlutathione precursor
- Omega-3-ACID ethyl esters
- MifepristoneGlucocorticoid receptor antagonist
- ScopolamineMuscarinic acetylcholine receptor M1 antagonist
- RiluzoleSodium channel alpha subunit blocker
- Taurine
- Nitrous oxide
- Creatine
- Uridine
- Cytidine
- CitalopramSerotonin transporter inhibitor
- FelbamateGlutamate [NMDA] receptor antagonist
Phase 1 or earlier 12 of 14
- PF-04455242
- DronabinolCannabinoid CB1 receptor agonist
- LY2979165Metabotropic glutamate receptor 2 agonist
- DextroamphetamineDopamine transporter releasing agent
- IbuprofenCyclooxygenase inhibitor
- PerampanelGlutamate receptor ionotropic AMPA antagonist
- VofopitantNeurokinin 1 receptor antagonist
- VixotrigineSodium channel protein type IX alpha subunit blocker
- Spiradoline
- MK-8189
- PentoxifyllineAdenosine A2 receptor antagonist
- CandesartanType-1 angiotensin II receptor antagonist
How its trials ended
1,493 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 395 whose ending is known, 51% met their primary endpoint, 9% missed it and 39% stopped early.
- Completed, result not reported70447%
- Ongoing24817%
- Met its primary endpoint20314%
- Status unknown14610%
- Stopped: other or unclear785%
- Stopped: enrollment or feasibility383%
- Missed its primary endpoint372%
- Stopped: funding181%
- Stopped: sponsor or business decision131%
- Stopped: lack of efficacy5<1%
- Stopped: safety3<1%
| Jun 11, 2026 | Optimizing the synergy between behavioural activation therapy and intravenous ketamine for treatment resistant depressionKetamine | University of Ottawa Institute of Mental Health Research | Pending |
| Mar 4, 2025 | Psilocybin-assisted therapy for treatment-resistant depression in bipolar ii disorder: a randomized controlled trialPsilocybin (PEX010) | University of British Columbia | Ongoing |
| Aug 25, 2022 | A multi-region, multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating SEP-4199 controlled release (CR) for the treatment…Aramisulpride-esamisulpride (SEP-4199) | Sumitomo Pharma | Closed |
| Aug 25, 2022 | A 12-month open-label extension study to evaluate the long-term safety, tolerability, and effectiveness of SEP-4199 controlled release (CR) for the treatment…Aramisulpride-esamisulpride (SEP-4199) | Sumitomo Pharma | Closed |
| Aug 3, 2022 | Psilocybin assisted therapy for anxiety and mood disorders: a transdiagnostic open label clinical trial for improving well-being (pam-well)Psilocybin | Brain and Cognition Discovery Foundation | Closed |
| Dec 6, 2021 | A pilot, randomized, placebo-controlled trial evaluating the treatment of premenstrual dysphoric disorder with oral contraceptives in bipolar disorderDrospirenone - ethinyl estradiol | Dr Benicio Frey | Closed |
| Jul 23, 2021 | Repeated ketamine infusions for treatment-resistant bipolar disorder: a randomized, double-blind, midazolam-controlled, phase II clinical trialKetamine | University Health Network | Ongoing |
| Jul 8, 2021 | Assessment of safety and feasibility of exablate neuro system to perform echo-focusing echo imaging in patients with treatment-resistant neurologic and…Definity (perflutren) | Insightec | Pending |
| Feb 12, 2021 | Efficacy of cariprazine in improving cognitive functioning in euthymic patients with bipolar i disorder: a proof of concept randomized, double blind placebo…Cariprazine | University of British Columbia | Closed |
| Feb 4, 2020 | Clinical trial protocol title: investigation of regional brain lactate elevation in subjects with bipolar disorderHyperpolarized pyruvate (13C) | Sunnybrook Research Institute | Pending |
| Feb 20, 2013 | AdasuveLoxapine | Ferrer Internacional S.A. | EMA ↗ |
| Sep 1, 2010 | SycrestAsenapine | Organon N.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA